Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05388006 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Richter Syndrome
Small Lymphocytic Lymphoma

Interventions

DRUG: Acalabrutinib
BIOLOGICAL: Durvalumab
DRUG: Venetoclax
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
PROCEDURE: Positron Emission Tomography (PET)
PROCEDURE: Computed Tomography

Sponsor

Mayo Clinic